CY1106644T1 - Ρυθμιστικα/αναδιπλωμενα πεπτιδια της εζρινης - Google Patents
Ρυθμιστικα/αναδιπλωμενα πεπτιδια της εζρινηςInfo
- Publication number
- CY1106644T1 CY1106644T1 CY20071100749T CY071100749T CY1106644T1 CY 1106644 T1 CY1106644 T1 CY 1106644T1 CY 20071100749 T CY20071100749 T CY 20071100749T CY 071100749 T CY071100749 T CY 071100749T CY 1106644 T1 CY1106644 T1 CY 1106644T1
- Authority
- CY
- Cyprus
- Prior art keywords
- ezrin
- hereceptor
- human
- amino acids
- charged molecules
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 230000001105 regulatory effect Effects 0.000 title abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 4
- 101000854648 Homo sapiens Ezrin Proteins 0.000 abstract 3
- 102100020903 Ezrin Human genes 0.000 abstract 2
- 108010055671 ezrin Proteins 0.000 abstract 2
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000000170 cell membrane Anatomy 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 230000001086 cytosolic effect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Rehabilitation Therapy (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Cell Biology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Αυτή η εφεύρεση περιγράφει νέα φορτισμένα μόρια που συνδέονται με εξειδικευμένο τρόπο με το Hepreceptor, μια ρυθμιστική θέση που ανακάλυψα στην ανθρώπινη εζρίνη. Η εφεύρεση μου είναι ότι όταν πεπτίδια ή άλλα φορτισμένα μόρια συνδέονται με το Hepreceptor, προκαλείται ιατρικώς χρήσιμη ανοσοαπόκριση. Αυτά τα φορτισμένα μόρια μπορούν να χορηγηθούν από το στόμα και με άλλες οδούς για τη θεραπεία διαφόρων μολυσματικών ασθενειών και του καρκίνου. Προσδιόρισα ότι το Hepreceptor (ανθρώπινη εζρίνη 308-373) αποτελείται από δύο γειτονικές περιοχές Α έλικας που διπλώνονται μαζί σε μια περιοχή αρμού (Μ339-Μ340) και σταθεροποιούνται με συμπληρωματικά πλευρικά φορτία της πρωτοταγούς αμινοξικής αλληλουχίας στην διαλυτή κυτταροπλασματική διαμόρφωση της εζρίνης. Προσδιόρισα ότι στην αναδιπλωμένη διάταξη μεμβρανικής σύνδεσης της εζρίνης, το Hepreceptor ωθείται μέσα από την κυτταρική μεμβράνη κι εκτείθεται στην εξωτερική επιφάνεια του κυττάρου. Η Περιοχή Α του Hepreceptor (αμινοξέα 308-339 της ανθρώπινης εζρίνης), περιέχει την παρακάτω αλληλουχία 32 αμινοξέων. SEQ DI 1 A R E E K H Q K Q L E R Q Q L E T E K K R R E T V E R E K E Q M. Η Περιοχή Β του Hepreceptor (αμινοξέα 340-373 της ανθρώπινης εζρίνης), περιέχει την παρακάτω αλληλουχία 34 αμινοξέων (Η τυροσίνη 353 [Υ] μπορεί να φωσφορυλιωθεί προς φωσφοτυροσίνη [Υp] στη διαμόρφωση μεμβρανικής σύνδεσης της εζρίνης): SEQ ID 2 M R E K E E L M L R L Q D Y (p) E E K T K K A E R E L S E Q I Q R A L Q.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9921881A GB2354241A (en) | 1999-09-17 | 1999-09-17 | Regulatory/unfolding peptides of ezrin |
PCT/GB2000/003566 WO2001025275A1 (en) | 1999-09-17 | 2000-09-15 | Regulatory/unfolding peptides of ezrin |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1106644T1 true CY1106644T1 (el) | 2012-01-25 |
Family
ID=10861009
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20071100749T CY1106644T1 (el) | 1999-09-17 | 2007-06-06 | Ρυθμιστικα/αναδιπλωμενα πεπτιδια της εζρινης |
Country Status (23)
Country | Link |
---|---|
US (1) | US6849596B1 (el) |
EP (2) | EP1131348B1 (el) |
JP (1) | JP2003511389A (el) |
KR (1) | KR20010101017A (el) |
CN (1) | CN100387619C (el) |
AT (1) | ATE356144T1 (el) |
AU (1) | AU770208B2 (el) |
BR (1) | BR0007158A (el) |
CA (1) | CA2348780A1 (el) |
CY (1) | CY1106644T1 (el) |
CZ (1) | CZ20011689A3 (el) |
DE (1) | DE60033783T2 (el) |
DK (1) | DK1131348T3 (el) |
ES (1) | ES2283317T3 (el) |
GB (1) | GB2354241A (el) |
HU (1) | HUP0104254A3 (el) |
NO (1) | NO20012417L (el) |
NZ (1) | NZ511747A (el) |
PL (1) | PL348635A1 (el) |
PT (1) | PT1131348E (el) |
RU (1) | RU2215005C2 (el) |
WO (1) | WO2001025275A1 (el) |
ZA (1) | ZA200103938B (el) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0301879D0 (en) * | 2003-01-27 | 2003-02-26 | Regent Res Llp | HCV combination therapy |
WO2007060440A2 (en) * | 2005-11-23 | 2007-05-31 | Regent Research L.L.P. | The use of peptides in anti-ulcer therapy |
CN100455665C (zh) * | 2006-11-21 | 2009-01-28 | 汕头大学医学院 | 人食管癌细胞ezrin基因上游转录调控元件 |
WO2009103312A1 (en) * | 2008-02-19 | 2009-08-27 | Ludwig-Maximilians-Universität | Ezrin, serpin b5, peroxiredoxin-2 and heat shock protein beta-1 as autoantigens for psoriasis and poststreptococcal diseases |
RU2580629C1 (ru) * | 2015-05-15 | 2016-04-10 | Федеральное государственное бюджетное учреждение "Научный центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения Российской Федерации | Способ прогнозирования рецептивности эндометрия на основании оценки экспрессии и внутриклеточной локализации эзрина в эндометрии женщин с бесплодием и повторными неудачами программы эко |
MD3191504T2 (ro) * | 2015-06-01 | 2018-04-30 | Nearmedic International Ltd | Peptide derivate din ezrin și compozițiile farmaceutice ale acestora |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2290293A (en) * | 1994-06-08 | 1995-12-20 | Rupert Donald Holms | Preparation which inhibits the autoimmune response in HIV, or SLE, patients |
WO1997012975A1 (en) | 1995-10-02 | 1997-04-10 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | An epithelial protein and dna thereof for use in early cancer detection |
US6399584B1 (en) * | 1998-03-18 | 2002-06-04 | Institute Curie | Pharmaceutical composition containing ezrin mutated on tyrosine 353 |
-
1999
- 1999-09-17 GB GB9921881A patent/GB2354241A/en not_active Withdrawn
-
2000
- 2000-09-15 CZ CZ20011689A patent/CZ20011689A3/cs unknown
- 2000-09-15 HU HU0104254A patent/HUP0104254A3/hu unknown
- 2000-09-15 CN CNB008022844A patent/CN100387619C/zh not_active Expired - Fee Related
- 2000-09-15 US US09/856,070 patent/US6849596B1/en not_active Expired - Fee Related
- 2000-09-15 AT AT00962685T patent/ATE356144T1/de not_active IP Right Cessation
- 2000-09-15 KR KR1020017006187A patent/KR20010101017A/ko not_active Application Discontinuation
- 2000-09-15 JP JP2001528215A patent/JP2003511389A/ja not_active Withdrawn
- 2000-09-15 EP EP00962685A patent/EP1131348B1/en not_active Expired - Lifetime
- 2000-09-15 DE DE60033783T patent/DE60033783T2/de not_active Expired - Fee Related
- 2000-09-15 RU RU2001113277/04A patent/RU2215005C2/ru not_active IP Right Cessation
- 2000-09-15 PL PL00348635A patent/PL348635A1/xx unknown
- 2000-09-15 DK DK00962685T patent/DK1131348T3/da active
- 2000-09-15 ES ES00962685T patent/ES2283317T3/es not_active Expired - Lifetime
- 2000-09-15 CA CA002348780A patent/CA2348780A1/en not_active Abandoned
- 2000-09-15 AU AU74333/00A patent/AU770208B2/en not_active Ceased
- 2000-09-15 WO PCT/GB2000/003566 patent/WO2001025275A1/en active IP Right Grant
- 2000-09-15 BR BR0007158-7A patent/BR0007158A/pt not_active IP Right Cessation
- 2000-09-15 NZ NZ511747A patent/NZ511747A/xx unknown
- 2000-09-15 EP EP06009089A patent/EP1760090A1/en not_active Withdrawn
- 2000-09-15 PT PT00962685T patent/PT1131348E/pt unknown
-
2001
- 2001-05-15 ZA ZA200103938A patent/ZA200103938B/en unknown
- 2001-05-16 NO NO20012417A patent/NO20012417L/no not_active Application Discontinuation
-
2007
- 2007-06-06 CY CY20071100749T patent/CY1106644T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
DE60033783D1 (de) | 2007-04-19 |
EP1131348B1 (en) | 2007-03-07 |
DK1131348T3 (da) | 2007-07-09 |
PT1131348E (pt) | 2007-11-19 |
AU7433300A (en) | 2001-05-10 |
NZ511747A (en) | 2004-03-26 |
GB9921881D0 (en) | 1999-11-17 |
ES2283317T3 (es) | 2007-11-01 |
ATE356144T1 (de) | 2007-03-15 |
WO2001025275A9 (en) | 2002-07-25 |
CN1327450A (zh) | 2001-12-19 |
NO20012417L (no) | 2001-07-16 |
BR0007158A (pt) | 2001-07-31 |
KR20010101017A (ko) | 2001-11-14 |
EP1131348A1 (en) | 2001-09-12 |
PL348635A1 (en) | 2002-06-03 |
WO2001025275A1 (en) | 2001-04-12 |
DE60033783T2 (de) | 2007-11-15 |
CA2348780A1 (en) | 2001-04-12 |
HUP0104254A3 (en) | 2002-05-28 |
GB2354241A (en) | 2001-03-21 |
JP2003511389A (ja) | 2003-03-25 |
US6849596B1 (en) | 2005-02-01 |
CZ20011689A3 (cs) | 2001-12-12 |
AU770208B2 (en) | 2004-02-19 |
RU2215005C2 (ru) | 2003-10-27 |
HUP0104254A2 (hu) | 2002-04-29 |
NO20012417D0 (no) | 2001-05-16 |
EP1760090A1 (en) | 2007-03-07 |
CN100387619C (zh) | 2008-05-14 |
ZA200103938B (en) | 2002-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1106644T1 (el) | Ρυθμιστικα/αναδιπλωμενα πεπτιδια της εζρινης | |
CY1119369T1 (el) | Ιατρικα παρασκευασματα για τη θεραπευτικη αγωγη της ανεπαρκειας της αλφα-γαλακτοσιδασης α | |
CY1108680T1 (el) | Σχετιζομενα με ογκους πεπτιδια δεσμευμενα σε μορια mhc | |
CY1118443T1 (el) | Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις | |
EA200901129A1 (ru) | Нуклеиновые кислоты и полипептиды нового рецептора | |
CY1113218T1 (el) | Υβριδιο και διμερης εκφραση πρωτεϊνων ναϊσσεριας | |
CY1105475T1 (el) | Συνθεσεις και μεθοδοι θepαπευτικης αγωγης νεοπλασματων | |
CY1117761T1 (el) | Απομονωση πεντε νεων γονιδιων που κωδικοποιουνται για νεους υποδοχεις μελανωματος fc που εμπλεκονται στην παθογενεση λεμφωματος/μελανωματος | |
BR0113420A (pt) | Anticorpos para il-1beta humano | |
BR0015103A (pt) | Compostos | |
AR038568A1 (es) | Anticuerpos anti-a beta y su uso | |
HUP0004639A2 (hu) | Chlamydia fehérje, génszekvencia és ezek alkalmazása | |
CY1109786T1 (el) | Μεθοδοι για την θεραπευτικη αγωγη ρευματικων ασθενειων με την χρησιμοποιηση ενος διαλυτου μοριου ctla4 | |
DE60039752D1 (de) | Herstellung tetravalenter antikörper | |
EA199901031A1 (ru) | Производные бензимидазола | |
TR199901710T2 (xx) | IL-8 resept�r antagonistleri. | |
ATE270303T1 (de) | Gc1q-rezeptor, daran bindende hiv-1 gp120-region, verwandte peptide und antikörper | |
RU2317998C2 (ru) | Антитела человека, обладающие активностью связывания c mn и нейтрализации клеточной адгезии | |
DE50112802D1 (de) | Peptide, deren herstellung und verwendung zur bindung von immunglobulinen | |
PT848720E (pt) | Antagonistas da actividade oncogenica da proteina mdm2 e sua utilizacao no tratamento de cancros | |
HUP0001136A2 (hu) | Limfatikus tumorok kezelésére szolgáló gyógyszerkészítmények | |
CY1108898T1 (el) | Προϊοντα συζευξης πεπτιδιων και πεπτιδομιμητικων ενωσεων με ιδιοτητες αναστολεα ενσωματινης | |
CY1108570T1 (el) | Gd3-μιμητικα πεπτιδια | |
DE69931482D1 (de) | Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen | |
DE69434961D1 (de) | Funktion und aktivität des viralen proteins r (vpr) |